common.study.topics.clinical

Testing Treatment for Prostate Cancer

common.study.values.description

Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to find out what effects a new drug, palbociclib, has on prostate cancer and will look at the side effects of treatment with palbociclib. The researchers doing this study are also interested in looking for markers that may help predict which patients are most likely to be helped by palbociclib and to see how the cancer cells respond to palbociclib.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - Palbociclib

125 mg orally on days 1-21 each 28 day cycle

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients With Metastatic Castration-Resistant Prostate Cancer

common.study.values.clinical-trial-id

NCT02905318

participant.views.study.view.id

Pe97Db